Synlogic SYBX
Synlogic FY 2023: revenue $3.4M, up 186%; diluted EPS −$8.81
- Form
- 10-K/A
- Filed
- Period
- Importance
- Routine
- Accession
- 0000950170-24-049810
- Document
- 10-K/A
Key figures from this report
These are the numbers Synlogic reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$3.4M+186% from $1.2M in FY 202210-K income statement, on EDGAR
- Net income−$57.3MAgainst −$66.1M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$8.81Against −$0.92 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$24.0M+51% from $15.9M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$51.6MAgainst −$56.9M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
- China Pharma Holdings CPHI public float $4M, Jun 30, 2025
- Soligenix SNGX public float $5M, Jun 30, 2025
- Target Group CBDY public float $5M, Jun 30, 2025
- Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
